Freelite™ Serum Free Light Chain Assays
This site is for Healthcare Professionals only
Click here for Patient Information
Latest News Headlines
Freelite is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia. There is now significant clinical evidence indicating the benefit of serum free light chain assays in initial screening for monoclonal gammopathies, identifying AL amyloidosis and Nonsecretory MM patients missed by conventional electrophoretic methods, for risk stratification of MGUS patients * and rapid evaluation of treatment efficacy.
Freelite assays were developed by Binding Site to measure free lambda and free kappa immunoglobulin light chains. Our expertise in the manufacture of antibodies has enabled us to provide a quantifiable, highly specific, automatable free light chain assay for serum.
Review the clinical evidence for the utility of Freelite in detecting and monitoring plasma cell disorders and compare the results from laboratory protocols with and without Freelite.
* In the USA diagnostic use of this product is restricted to those stated in the product insert
Latest News 09 June 2008
First myeloma kidney patient recruited onto EuLITE clinical trial
Binding Site announces the launch of a new clinical trial for patients suffering from myeloma kidney with the recruitment of the first patient onto the EuLITE trial.
EuLITE is a randomised control trial being carried out across a number of British and German Acute nephrology units. It combines use of Freelite™ to monitor levels of nephrotoxic free light chains in serum, light chain removal using a high cut off haemodialysis filter (HCO1100, Gambro) and tumour kill with Velcade-based chemotherapy, with the aim of restoring renal function in patients with myeloma kidney.
EuLITE is based on a pilot study conducted at the Queen Elizabeth Hospital, Birmingham. Renal function was restored in over 70% of myeloma patients treated with high cut off haemodialysis and chemotherapy. This represents a significant improvement over historical controls in which only 11% became dialysis-independent. Restoring renal function in myeloma patients is associated with an increase in life expectancy from 6 months to several years and dramatic gains in quality of life. More
